PMID- 29197348
OWN - NLM
STAT- MEDLINE
DCOM- 20180718
LR  - 20181113
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Dec 2
TI  - Hyperbaric oxygen treatment and nephrotoxicity induced by gentamicin in rats.
PG  - 347
LID - 10.1186/s12882-017-0768-2 [doi]
LID - 347
AB  - BACKGROUND: Nephrotoxicity is a significant adverse side effect of gentamicin. 
      Previous preclinical studies showed that hyperbaric oxygen treatment (HBOT) may 
      have beneficial effects by attenuating renal damage in rats subjected to renal 
      injury. We evaluated the effect of HBOT on acute renal failure caused by 
      gentamicin. METHODS: Thirty-six rats were divided into four groups. Gentamicin 
      (150 mg/kg for 5 consecutive days) was administered in 30 rats, 10 rats received 
      only gentamicin, 10 rats received 100% oxygen therapy on days 1-5 of the 
      experiment, 10 received daily HBOT on days 1-5 of the experiment, and the 
      remaining six served as a control group. On day 6, renal function tests and renal 
      pathological examinations were performed. RESULTS: Body weight and biochemical 
      parameters were similar in all groups except for higher plasma levels of calcium 
      in the 100% oxygen group (P = 0.03). All the rats in the experimental group 
      showed biochemical parameters compatible with renal failure (high serum levels of 
      urea and creatinine). All the rats in the control group had normal renal function 
      tests. Two rats from the HBOT group died on the fifth day of the experiment. All 
      rats in the control group demonstrated normal renal morphology. All 28 
      intoxicated rats showed moderate to severe histopathological changes without 
      significant differences between the groups. CONCLUSIONS: Treatment of 
      gentamicin-induced nephrotoxicity with either HBOT or 100% oxygen for 5 days had 
      no beneficial renal effect. Mortality was observed only in the HBOT group.
FAU - Berkovitch, Matitiahu
AU  - Berkovitch M
AD  - Pediatric Division, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Shain, Yossi
AU  - Shain Y
AD  - Pediatric Division, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Kozer, Eran
AU  - Kozer E
AD  - Pediatric Division, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Goldman, Michael
AU  - Goldman M
AD  - Pediatric Division, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Abu-Kishk, Ibrahim
AU  - Abu-Kishk I
AD  - Pediatric Division, Assaf Harofeh Medical Center, 70300, Zerifin, Israel. 
      ibrahima@asaf.health.gov.il.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 
      ibrahima@asaf.health.gov.il.
LA  - eng
PT  - Journal Article
DEP - 20171202
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Gentamicins)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced/pathology/*therapy
MH  - Animals
MH  - Anti-Bacterial Agents/*toxicity
MH  - Gentamicins/*toxicity
MH  - Hyperbaric Oxygenation/*methods
MH  - Kidney Function Tests/methods
MH  - Male
MH  - Pilot Projects
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC5712188
OTO - NOTNLM
OT  - Gentamicin
OT  - Hyperbaric oxygen therapy
OT  - Nephrotoxicity
OT  - Rat model
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: This study was approved by the Assaf 
      Harofeh Medical Center Animal Care Committee. The rats were handled according to 
      the guidelines of the Local Ethics Committee for Animal Experimentation. CONSENT 
      FOR PUBLICATION: Not applicable. COMPETING INTEREST: The authors declare that 
      they have no competing interest. PUBLISHER'S NOTE: Springer Nature remains 
      neutral with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2017/12/05 06:00
MHDA- 2018/07/19 06:00
PMCR- 2017/12/02
CRDT- 2017/12/04 06:00
PHST- 2017/06/03 00:00 [received]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/12/04 06:00 [entrez]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2018/07/19 06:00 [medline]
PHST- 2017/12/02 00:00 [pmc-release]
AID - 10.1186/s12882-017-0768-2 [pii]
AID - 768 [pii]
AID - 10.1186/s12882-017-0768-2 [doi]
PST - epublish
SO  - BMC Nephrol. 2017 Dec 2;18(1):347. doi: 10.1186/s12882-017-0768-2.